Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$13.6m

Cyclerion Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Regina Graul

Chief executive officer

US$572.2k

Total compensation

CEO salary percentage73.41%
CEO tenure2.5yrs
CEO ownership1.6%
Management average tenureno data
Board average tenure1.8yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 06

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Cyclerion Therapeutics (NASDAQ:CYCN) on Thursday said it would reduce its workforce by about 45% as part of a strategic prioritization to focus its resources on the development of its therapy CY6463 for the treatment of mitochondrial diseases. Shares of the micro-cap clinical-stage biopharma slumped 32% to $0.64 in morning trading. CYCN said it expects to take a one-time charge related to the workforce reduction of about $1.9M that would be incurred primarily in Q4 2022. The company will first concentrate its development of CY6463 for MELAS, which is a mitochondrial disease that primarily affects the nervous system and muscles. CYCN plans to meet with the U.S. FDA in Q4 to discuss the MELAS development program. The company also said it intends to leverage its other clinical assets through licensing agreements and partnership.
Analysis Article • Aug 09

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 03

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 26

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distressed company. As a result, the company is one to monitor over the next few months and wait to potentially buy the stock after new clinical data is reported.
Seeking Alpha • Jun 21

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463. The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021. With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.
Analysis Article • Mar 09

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Analysis Article • Jan 28

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

A look at the shareholders of Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) can tell us which group is most powerful...
Analysis Article • Dec 20

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

The last three months have been tough on Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) shareholders, who have seen the...

CEO Compensation Analysis

How has Regina Graul's remuneration changed compared to Cyclerion Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$5m

Dec 31 2025US$572kUS$420k

-US$4m

Sep 30 2025n/an/a

-US$2m

Jun 30 2025n/an/a

-US$2m

Mar 31 2025n/an/a

-US$3m

Dec 31 2024US$875kUS$391k

-US$3m

Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$496kUS$31k

-US$13m

Compensation vs Market: Regina's total compensation ($USD572.15K) is about average for companies of similar size in the US market ($USD649.92K).

Compensation vs Earnings: Regina's compensation has been consistent with company performance over the past year.

CEO

Regina Graul (48 yo)

2.5yrs
Tenure
US$572,153
Compensation

Dr. Regina M. Graul, Ph.D. is President of Cyclerion Therapeutics, Inc. from December 01, 2023 and serves as its Chief Executive Officer and Director since August 2024. Dr. Graul joined Cyclerion on Decemb...

Board Members

NamePositionTenureCompensationOwnership
Regina Graul
CEO, President & Director1.8yrsUS$572.15k1.62%
$ 220.1k
Lawrence Olanoff
Member of Clinical Advisory Boardless than a yearno datano data
Peter Hecht
Director7.2yrsno data13.18%
$ 1.8m
Errol De Souza
Independent Chairman5.2yrsno data1.18%
$ 160.5k
Steven Hyman
Independent Director3.9yrsno data0.47%
$ 64.2k
Michael Higgins
Independent Director2.6yrsno data0.72%
$ 98.7k
Husseini Manji
Member of Clinical Advisory Boardless than a yearno datano data
Linda Carpenter
Member of Clinical Advisory Boardless than a yearno datano data
Dina Katabi
Independent Director2.5yrsno data0.47%
$ 64.2k
Yuriy Bronshteyn
Member of Clinical Advisory Boardless than a yearno datano data
Laeben Lester
Member of Clinical Advisory Boardless than a yearno datano data
1.8yrs
Average Tenure
65.5yo
Average Age

Experienced Board: CYCN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 06:24
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cyclerion Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Joon So LeeTruist Securities
David BautzZacks Small-Cap Research